Gene Editing Cell Therapy and Non-Addictive Painkiller: Vertex's Success

This chapter highlights the recent success of Vertex Pharmaceuticals, with the FDA approving their gene editing cell therapy for sickle cell disease, making it the first of its kind. It also discusses the positive phase two clinical trial for Vertex's new non-addictive painkiller, which shows promising results in treating diabetic nerve pain.